Rosuvastatin-Vial - Instructions For Use, Reviews, Price Of Tablets

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Rosuvastatin Vial

Rosuvastatin-Vial: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Rosuvastatin-Vial

ATX code: C10AA07

Active ingredient: rosuvastatin (Rosuvastatin)

Manufacturer: Protek Biosystems Pvt. Ltd. (Protech biosystems Pvt. Ltd.) (India)

Description and photo update: 2019-09-07

Prices in pharmacies: from 280 rubles.

Buy

Rosuvastatin Vial is a drug that helps to lower blood lipids.

Release form and composition

A lipid-lowering agent is produced in the form of film-coated tablets: biconvex, round, the core in cross-section and the film shell is almost white or white; dosage of 10 mg - with a risk on one side (10 pcs. in a blister, 40 or 50 pcs. in a high-density polyethylene container; in a cardboard box 3 blisters or 1 container and instructions for use of Rosuvastatin-Vial).

1 tablet contains:

• active substance: rosuvastatin calcium - 10.42 or 20.84 mg (which in terms of rosuvastatin is 10 or 20 mg, respectively);
• additional components (core): sodium carboxymethyl starch, microcrystalline cellulose, sodium croscarmellose, corn starch, lactose monohydrate, colloidal silicon dioxide, magnesium stearate, propyl parahydroxybenzoate, talc, methyl parahydroxybenzoate;
• film shell: dibutylsebakat, hypromellose 15cP, colloidal silicon dioxide, titanium dioxide, talc, hypromellose 5cP.

Pharmacological properties

Pharmacodynamics

Rosuvastatin is a selective competitive inhibitor of HMG-CoA reductase, an enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, which is a precursor of cholesterol (CS). The action of the lipid-lowering substance is directed mainly at the liver - the organ in which the synthesis of Xc and the catabolism of low-density lipoproteins (LDL) is carried out. It promotes an increase in the number of LDL receptors on the surface of liver cells, which leads to inhibition of the production of very low density lipoproteins (VLDL), and thereby causes a decrease in the total number of LDL and VLDL.

Rosuvastatin lowers the level of total cholesterol (HC), triglycerides (TG), cholesterol-LDL, and increases the level of high-density lipoprotein cholesterol (HDL-cholesterol). In addition, it reduces the level of apolipoprotein B (ApoB), Xc-VLDL, TG-VLDL, Xc-non-HDL, and increases the concentration of apolipoprotein AI (ApoA-I), while providing a decrease in the ratio of TC / HDL-C, LDL-C / Xc-HDL and Xs-non-HDL / Xc-HDL, and the ApoV / ApoA-I ratios.

The therapeutic effect of Rosuvastatin-Vial appears within 7 days after the start of the course, and after 14 days it reaches 90% of the maximum possible level. By 28 days of admission, as a rule, the maximum therapeutic effect is observed, which subsequently persists with regular administration of the drug.

Rosuvastatin-Vial therapy is effective in adult patients with / without hypercholesterolemia, including patients with familial hypercholesterolemia and diabetes mellitus. In 80% of individuals with Fredrickson type IIa and IIb hypercholesterolemia (mean baseline LDL-C level of about 4.8 mmol / L), LDL-C was noted at the level of values less than 3 mmol / L. If patients had heterozygous familial hypercholesterolemia while taking rosuvastatin in doses of 20–80 mg, positive changes in the lipid spectrum were observed. After 12 weeks of therapy, when a daily dose of 40 mg was reached, a decrease in the level of LDL-C was recorded by 53%.

In patients with homozygous familial hypercholesterolemia, who took the drug at a dose of 20 and 40 mg, the concentration of LDL-C decreased on average by 22%. With the combined use of rosuvastatin with fenofibrate, an additive effect is observed in relation to the level of TG, and with niacin in daily doses of more than 1000 mg - in relation to HDL cholesterol.

Pharmacokinetics

After oral administration, the maximum plasma concentration of rosuvastatin (C _max) in the blood is observed on average after 5 hours. The absolute bioavailability of the active substance is approximately 20%, metabolic transformation is performed mostly by the liver, which is the main site of the metabolism of LDL-C and cholesterol production. The volume of distribution (V _d) of rosuvastatin is approximately 134 liters, with plasma proteins, mainly albumin, the agent binds to an average of 90%.

The substance undergoes metabolism to a small extent (approximately 10%), is a non-core substrate for metabolic transformation by isoenzymes of the cytochrome P _{450 system}. The main isoenzyme responsible for the biotransformation of the drug is CYP2C9, isoenzymes CYP3A4, CYP2C19 and CYP2D6 are also involved in this process, but to a lesser extent.

Among the identified metabolites of rosuvastatin, the main ones are lactone metabolites and N-desmethyl. Moreover, the latter has an activity of about 50% less than rosuvastatin. Lactone metabolites are classified as pharmacologically inactive. More than 90% of the inhibitory effect on the circulating HMG-CoA reductase is rosuvastatin, and 10% is its metabolites.

Excreted through the intestine in unchanged form, approximately 90% of the dose of the active substance (including absorbed and unabsorbed rosuvastatin). The remainder of the drug is excreted by the kidneys. The half-life (T _1/2) from plasma is approximately 19 hours and remains unchanged with increasing dose. The geometric mean plasma clearance is approximately 50 l / h. In the course of hepatic elimination of rosuvastatin, an important role is played by the Xc membrane transporter.

The systemic exposure of the substance increases in proportion to the dose; against the background of its daily intake, there are no changes in pharmacokinetic parameters.

Age and gender do not significantly affect the pharmacokinetic characteristics of the drug.

In the course of pharmacokinetic studies, it was found that in patients of the Mongoloid race (Vietnamese, Chinese, Japanese, Koreans and Filipinos) the median AUC (area under the concentration-time pharmacokinetic curve) and C _{max of} rosuvastatin were approximately 2 times increased, when compared with representatives of the Caucasian race. In Indian patients, these indicators were increased by 1.3 times. Among the representatives of the Caucasian and Negroid races, no significant differences in the pharmacokinetics of the drug were found.

Indications for use

• primary hypercholesterolemia according to the Fredrickson classification (type IIa; including familial heterozygous hypercholesterolemia) or mixed hypercholesterolemia (type IIb): as a supplement to the diet, in cases where exercise, special diet, weight loss and other non-drug treatment methods are insufficient;
• familial homozygous hypercholesterolemia: as an adjunct to diet and other lipid-lowering treatments (including LDL apheresis) or in cases where such therapy does not achieve the desired effect;
• hypertriglyceridemia (type IV according to Fredrickson's classification): as a supplement to the diet;
• heart attack, stroke, arterial revascularization and other major cardiovascular complications in adults: for the purpose of primary prevention in the absence of clinical signs of coronary heart disease (CHD), but with an aggravation of the threat of its appearance (for men / women, age over 50/60 years; concentration C-reactive protein, exceeding 2 mg / L, in the presence of at least one of the additional risk factors, including arterial hypertension, family history of early onset of coronary artery disease, low HDL-C, smoking);
• atherosclerosis (in order to slow down its progression): as an addition to the diet in cases where treatment is indicated to reduce the level of TC and LDL-C.

Contraindications

Absolute contraindications for all daily doses of Rosuvastatin-Vial:

• liver failure;
• liver disease in the active stage, including a persistent increase in serum transaminase activity and any serum increase in transaminase activity in the blood - more than 3 times when compared with the upper limit of normal (UHN);
• severe renal dysfunction, with creatinine clearance (CC) less than 30 ml / min;
• lactase deficiency, lactose intolerance, glucose-galactose malabsorption (the tablets contain lactose);
• combined use with cyclosporine;
• age up to 18 years;
• pregnancy, lactation period; in women of reproductive age - the lack of reliable methods of contraception;
• hypersensitivity to any component of the drug.

Additional absolute contraindications when using a dose of 5, 10 or 20 mg / day:

• myopathy;
• predisposition to the appearance of myotoxic complications.

Additional absolute contraindications when using a dose of 40 mg / day:

• impaired renal function of moderate severity, with CC less than 60 ml / min;
• conditions against which the concentration of rosuvastatin in plasma may increase;
• the presence of risk factors for myopathy / rhabdomyolysis: hypothyroidism, renal failure, personal / family history of muscle lesions, history of myotoxicity during therapy with other HMG-CoA reductase inhibitors or fibrates;
• belonging to the Mongoloid race;
• excessive alcohol consumption;
• concomitant treatment with fibrates.

Relative contraindications for all daily doses of Rosuvastatin-Vial (for the following diseases / conditions, the agent must be used with caution):

• arterial hypotension;
• sepsis;
• a history of liver disease;
• age over 65;
• trauma, major surgical interventions;
• uncontrolled seizures, severe electrolyte, metabolic or endocrine disorders.

Additional relative contraindications when using 5, 10 or 20 mg / day:

• conditions accompanied by an increase in the plasma level of rosuvastatin;
• belonging to the Mongoloid race;
• simultaneous reception with fibrates;
• alcohol abuse;
• the presence of a threat of myopathy / rhabdomyolysis: hypothyroidism, renal failure, aggravated personal / family history of muscle disease, previous history of muscle toxicity during therapy with fibrates or other inhibitors of HMG-CoA reductase.

An additional relative contraindication for the use of Rosuvastatin Vial at a dose of 40 mg / day is mild renal failure (CC above 60 ml / min).

Rosuvastatin-Vial, instructions for use: method and dosage

Rosuvastatin Vial is taken orally. The tablets are swallowed whole, without chewing or crushing, with water.

The drug can be used at any time of the day, food intake does not affect its effectiveness. Before the start of the course of therapy and during its implementation, it is necessary to follow a standard cholesterol-lowering diet. The dose of rosuvastatin is set individually, taking into account the goals of treatment and the therapeutic response to taking the drug, guided by the current recommendations for the target lipid concentration.

Patients who have not previously received drugs from the statin group, or who have taken other HMG-CoA reductase inhibitors before starting rosuvastatin therapy, are recommended to use Rosuvastatin-Vial 1 time per day at a dose of 5 or 10 mg. When choosing an initial dose, one should take into account the existing risk of developing cardiovascular complications, individual cholesterol concentration and the possibility of adverse reactions. A higher dose of the drug can be prescribed 4 weeks after the start of the course.

The threat of side effects is aggravated by taking Rosuvastatin-Vial in a daily dose of 40 mg, therefore, this dose can be prescribed (after additional use of a dose exceeding the initial dose for 4 weeks) only in case of severe hypercholesterolemia and a high probability of cardiovascular complications (especially in familial hypercholesterolemia), if the desired result could not be achieved after prescribing a dose of 20 mg. Therapy must be carried out under the strict supervision of a specialist. Patients receiving the drug in a daily dose of 40 mg require the most careful monitoring.

Patients who have not previously sought medical help should not use Rosuvastatin-Vial at a dose of 40 mg. After 2–4 weeks after the start of therapy and / or with an increase in the dose, it may be necessary to monitor the parameters of lipid metabolism with subsequent dose adjustment if necessary.

Since an increase in the systemic concentration of rosuvastatin was recorded in patients of the Mongoloid race, when they are prescribed a dose of 10/20 mg, the recommended initial dose of the drug should not exceed 5 mg. Patients of Asian origin should not be prescribed Rosuvastatin Vial 40 mg.

If there is a predisposition to the onset of myopathy, the drug should be used in an initial dose of 5 mg, the maximum allowable dose for such patients is 20 mg.

In patients with c.421AA or c.521CC genotypes, the recommended maximum daily dose of Rosuvastatin-Vial should also not exceed 20 mg.

Side effects

Side effects recorded during rosuvastatin therapy usually go away on their own and are mild. The incidence of these disorders is usually dose-dependent.

The likelihood of unwanted adverse reactions, according to the classification of the WHO (World Health Organization) [scale: often (more than 1/100, but less than 1/10); infrequently (more than 1/1000, but less than 1/100); rarely (more than 1/10 000, but less than 1/1000); extremely rare (less than 1/10 000), including individual episodes; frequency not established (cannot be calculated from available data)]:

• central nervous system: often - dizziness, headache;
• endocrine system: often - type 2 diabetes mellitus;
• immune system: rarely - angioedema and other possible hypersensitivity reactions;
• digestive system: often - nausea, abdominal pain, constipation; rarely - pancreatitis;
• liver: rarely - increased activity of hepatic transaminases, in most cases dose-dependent, insignificant, asymptomatic and transient;
• musculoskeletal system: often - myalgia; rarely - rhabdomyolysis (with the possible development of acute renal failure, especially when using doses above 20 mg), myopathy, including myositis; in some cases - a dose-dependent increase in the activity of creatine phosphokinase (CPK), mainly temporary, asymptomatic and to a small extent; in case of an increase in the level of CPK, more than 5 times higher than VGN, treatment should be discontinued;
• skin: infrequently - rash, skin itching, urticaria;
• laboratory parameters: an increase in the level of glucose, bilirubin, alkaline phosphatase (ALP), gamma-glutamyltranspeptidase (GGTP) activity, thyroid disorders;
• urinary system: proteinuria (usually decreases / disappears during therapy and does not indicate the appearance of an acute lesion or aggravation of the existing kidney disease);
• others: often - asthenic syndrome.

During the period of post-marketing use of rosuvastatin, the following undesirable effects were recorded:

• central nervous system: extremely rare - memory loss / decrease; with an unspecified frequency - peripheral neuropathy;
• musculoskeletal system: extremely rare - arthralgia; with an unknown frequency - immune-mediated necrotizing myopathy;
• urinary system: extremely rare - hematuria;
• hematopoietic system: with an unknown frequency - thrombocytopenia;
• digestive system: rarely - an increase in the level of hepatic transaminases; extremely rare - jaundice, hepatitis; with an unknown frequency - diarrhea;
• skin and subcutaneous fat: with an unknown frequency - Stevens-Johnson syndrome;
• reproductive system: extremely rare - gynecomastia;
• respiratory system: with an unknown frequency - shortness of breath, cough;
• others: with an unknown frequency - peripheral edema.

During the period of treatment with some statins, the following disorders were noted: hyperglycemia, depression, sexual dysfunction, sleep disorders, including nightmares and insomnia, an increase in the content of glycosylated (glycated) hemoglobin.

There were isolated cases of interstitial lung disease, mainly during long-term treatment. Symptoms of this complication may include weight loss, weakness, shortness of breath, fever, and unproductive cough. It is necessary to discontinue therapy if you suspect the development of this adverse reaction.

Overdose

The pharmacokinetic characteristics of rosuvastatin do not change when several daily doses are taken together.

If an overdose is suspected, it is recommended to carry out symptomatic therapy and measures aimed at maintaining the activity of vital systems and organs. Monitoring of liver function and CPK level is shown, hemodialysis is considered inappropriate.

special instructions

When using Rosuvastatin-Vial, mainly at a dose of 40 mg, tubular proteinuria may develop, usually of a transient nature. This reaction does not confirm exacerbation / progression of kidney damage. When prescribing the drug in a dose of 40 mg during treatment, regular monitoring of the indicators of the functional state of the kidneys should be carried out.

The CPK level should not be set after significant physical exertion or in the presence of any other possible reasons for the increase in its activity, in order to correctly interpret the results of the tests performed. If, before the start of the course, the initial CPK level is significantly increased (more than 5 times higher than the ULN), a second test is required after 5-7 days. When repeated results confirm the baseline, therapy is not initiated.

In case of sudden muscle pain, muscle weakness or spasms during therapy, especially in combination with the development of malaise and fever, you should immediately consult a doctor. In the presence of such symptoms, the activity of CPK should be established. If these violations are pronounced, even with an increase in the level of CPK less than 5 times compared with VGN, it is required to stop treatment. When relieving symptoms and normalizing the CPK level, you can consider re-using Rosuvastatin-Vial at lower doses while ensuring careful monitoring of the patient's condition. Continuous monitoring of CPK activity in the absence of symptoms is inappropriate.

During the use or withdrawal of statins (including rosuvastatin), extremely rare cases of the development of immune-mediated necrotizing myopathy have been recorded, the manifestations of which are persistent weakness of the proximal muscles and an increase in serum CPK activity. In this case, additional examinations of the muscular and nervous systems, serological studies, and treatment with immunosuppressive drugs may be necessary.

During treatment with rosuvastatin and concomitant therapy, no increased effect on skeletal muscles was found. However, there are reports of an increase in the occurrence of myopathy and myositis in patients who received other HMG-CoA reductase inhibitors in combination therapy with fibric acid derivatives (gemfibrozil), cyclosporine, nicotinic acid in lipid-lowering doses (more than 1000 mg per day), macrolide antibiotics, human immunodeficiency virus (HIV) protease inhibitors, azole antifungal agents. Gemfibrozil aggravates the threat of myopathy when used in combination with some HMG-CoA reductase inhibitors (the combination with rosuvastatin is not recommended).

Benzoates present in Rosuvastatin-Vial can lead to the development of allergic reactions (including delayed ones).

In patients with a glucose concentration of 5.6 to 6.9 mmol / L, the use of rosuvastatin aggravates the risk of developing type 2 diabetes mellitus.

Influence on the ability to drive vehicles and complex mechanisms

Studies to determine the effect of Rosuvastatin-Vial on the ability to control technically complex and potentially dangerous mechanisms have not been conducted. However, it is recommended to be careful when working with equipment and driving vehicles due to the possible appearance of dizziness during therapy.

Application during pregnancy and lactation

For pregnant and lactating women, lipid-lowering therapy is contraindicated.

While taking Rosuvastatin-Vial, women of childbearing age need to use reliable contraception. In the event of pregnancy during treatment, the course should be stopped immediately.

There is no data on the excretion of rosuvastatin in human milk, as a result of which, during breastfeeding, the use of the drug must be discontinued.

Pediatric use

It is contraindicated to prescribe Rosuvastatin-Vial tablets to patients under 18 years of age due to the lack of data confirming the effectiveness and safety of drug therapy in children and adolescents.

With impaired renal function

In patients with severe renal impairment (CC below 30 ml / min), the plasma levels of rosuvastatin and N-desmethyl were 3 and 9 times higher, respectively, than those in healthy volunteers. In patients undergoing hemodialysis treatment, the concentration of the substance in the blood plasma was on average 50% higher than in healthy volunteers. In the presence of mild to moderate renal failure, the plasma levels of rosuvastatin or N-desmethyl did not change.

The use of Rosuvastatin-Vial tablets in all daily doses is contraindicated in patients with severe renal impairment (CC below 30 ml / min), and at a dose of 40 mg - in addition to patients with moderate impairments (CC below 60 ml / min). The initial dose of rosuvastatin in the presence of moderate renal impairment should be 5 mg. With mild renal failure (CC above 60 ml / min), the drug at a dose of 40 mg should be taken with caution.

For violations of liver function

In patients with liver failure, the severity of which on the Child-Pugh scale was 7 and below points, there was no increase in T _{1/2 of} rosuvastatin, in patients with 8 and 9 points, an increase in T _1/2 was observed at least 2 times … There is no experience of treatment with rosuvastatin in patients whose condition on the Child-Pugh scale is higher than 9 points.

Taking Rosuvastatin-Vial is contraindicated in the presence of liver failure, active stage of liver disease, including a persistent increase in serum transaminase activity and any serum increase in transaminase activity in the blood by more than 3 times in comparison with VGN.

Rosuvastatin Vial should be used with caution in patients with a history of liver disease. It is recommended to determine the indicators of liver activity before treatment with the drug and 3 months after the start of the course.

Use in the elderly

Patients over 65 years of age should be treated with the drug with caution. Patients over 70 are advised to start taking Rosuvastatin-Vial with a dose of 5 mg. No other adjustment of the dosage regimen associated with old age is required.

Drug interactions

• cyclosporine: there is an increase in the AUC of rosuvastatin 7 times higher than that observed in healthy volunteers; the plasma level of cyclosporine does not change, this combination is contraindicated;
• drugs that are inhibitors of transport proteins BCRP and OATP1B1: there is an increase in the plasma level of rosuvastatin and an aggravation of the risk of myopathy;
• gemfibrozil and other drugs with a hypolipidemic effect: a 2-fold increase in the C _max in blood plasma and AUC of rosuvastatin is recorded; there may be a pharmacodynamic interaction with fenofibrate, a significant pharmacokinetic interaction of these funds is not expected;
• fenofibrate, gemfibrozil, other fibrates and nicotinic acid in lipid-lowering doses (1000 mg per day or more): the threat of myopathy increases when combined with HMG-CoA reductase inhibitors, presumably due to the fact that they can lead to myopathy and when used in monotherapy mode; when conducting a combination treatment, after a thorough assessment of the ratio of the potential risk and the expected benefits of using these drugs, patients are recommended to take rosuvastatin at a dose of 5 mg at the beginning of the course; while taking rosuvastatin with fibrates in a daily dose of 40 mg is contraindicated;
• atazanavir, tipranavir and / or lopinavir and other HIV protease inhibitors: there may be a pronounced increase in rosuvastatin exposure (the exact mechanism of interaction has not been established); simultaneous use is not recommended;
• warfarin and other vitamin K antagonists (indirect anticoagulants): an increase in the international normalized ratio (INR) may be observed, and against the background of cancellation or in the case of a decrease in the dose of rosuvastatin, a decrease in MHO, therefore, monitoring of this indicator is required;
• ezetimibe: a significant increase in the AUC of rosuvastatin was recorded when it was taken at a dose of 10 mg in combination with ezetimibe at a similar dose in patients with hypercholesterolemia; there may be an increase in the risk of adverse reactions as a result of the pharmacodynamic interaction of these substances;
• erythromycin: a decrease in C _max in the blood and AUC of rosuvastatin due to increased intestinal motility associated with treatment with erythromycin;
• ketoconazole (an inhibitor of CYP3A4 and CYP2A6 isoenzymes), fluconazole (an inhibitor of CYP3A4 and CYP2C9 isoenzymes): no clinically significant interaction was found with combination therapy;
• antacids (in the form of suspensions containing aluminum and magnesium hydroxide): the C _{max of} rosuvastatin in plasma decreases by an average of 50%. The severity of this effect decreases if antacids are taken 2 hours after using rosuvastatin; the significance of this interaction has not been established;
• hormone replacement therapy / oral contraceptives: there was an increase in the AUC values of ethinyl estradiol and norgestrel; these changes should be taken into account when establishing doses of hormonal drugs; this combination has been widely used in clinical trials and is generally well tolerated by patients;
• cytochrome P ₄₅₀ isozymes: no interaction of rosuvastatin with other agents / substances due to metabolism mediated by cytochrome P ₄₅₀ isoenzymes is expected;
• digoxin: no clinically significant interaction expected;
• drugs that increase exposure to rosuvastatin: it is required to adjust the dose of rosuvastatin if it is necessary to take it simultaneously with these drugs.

Analogs

Rosuvastatin-Vial analogues are Rosuvastatin-SZ, Akorta, Lipoprime, Krestor, Rozistark, Rosulip, Mertenil, Tevastor, Reddistatin, Rosufast, Rosart, etc.

Terms and conditions of storage

Store at a temperature not exceeding 25 ° C, out of reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews of Rosuvastatin-Vial

According to reviews, Rosuvastatin Vial is an effective drug used for the treatment of hypercholesterolemia, slowing the progression of atherosclerotic lesions and primary prevention of cardiovascular complications.

Patients note that Rosuvastatin Vial provides a significant decrease in blood cholesterol levels and helps to normalize blood pressure. At the same time, they emphasize that in order to effectively lower cholesterol, drug treatment must be combined with a strict low-cholesterol diet and regular exercise.

The disadvantage of a lipid-lowering agent is a large number of side effects.

The price of Rosuvastatin-Vial in pharmacies

There is no reliable information on the price of Rosuvastatin-Vial, since the drug is currently not available in the pharmacy network.

The cost of an analogue of the drug, Rosuvastatin-SZ, (film-coated tablets, 30 pcs. In a package) depends on the dosage and can be:

• tablets 10 mg - 270-370 rubles;
• tablets 20 mg - 370-430 rubles;
• tablets 40 mg - 580-810 rubles.

Rosuvastatin Vial: prices in online pharmacies

Drug name Price Pharmacy

Rosuvastatin-Vial 20 mg film-coated tablets 30 pcs. 280 RUB Buy

Rosuvastatin-Vial 10 mg film-coated tablets 30 pcs. 286 r Buy

Rosuvastatin-Vial tablets p.o. 10mg 30 pcs. RUB 291 Buy

Rosuvastatin-Vial tablets p.o. 20mg 30 pcs. 366 r Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!